Episode Details
Back to Episodes
The $215 Billion Tollbooth: Anatomy of an Engineered Bottleneck
Description
We tolerate a financial structure in healthcare that would get a procurement manager fired in any other industry.
Out of the $650 billion spent annually on drugs in the U.S., roughly $215 billion is captured by intermediaries.
The system is not broken; it is functioning exactly as its contracts dictate.
-----------------
Pharmacy Benefit Managers (PBMs) are compensated based on a percentage of drug list prices.
They are financially incentivised to ignore cheap generics and push expensive, high-rebate drugs.
-----------------
In this episode, we break down the mechanics of the gross-to-net pricing bubble.
We bypass the standard industry outrage to look directly at the math, the measurement blind spots, and the waste flow.
-----------------
Inside the Episode:
Why your cost-containment dashboards are showing record savings while your actual spending goes up.
The mechanics of how percentage-based rebates block biosimilar adoption.
How to execute a one-week, zero-capex formulary audit on your top 20 drugs.
The financial impact of moving to a flat administrative fee (projected to compress spend by up to 15%).
-----------------
If you are a finance or operations leader relying on aggregate rebate reporting, you are measuring the size of your blind spot.
Listen in to learn how to measure the baseline.
-----------------
Stay Tuned…
Regards, Top Voice
Maido & Kon'nichiwa min'na! 👶🏻🧑🏻🦱👩🏻🦳
Wie Geht's guys? Mir geht's gut!!! ✌️🤘🙌
#SupplyChain
#OperationalExcellence
#FinOps
#HealthcareFinance
#SystemDesign
#ProcessEngineering
#OperationsManagement
#IndustrialEngineering
#SystemsThinking
#SupplyChainManagement
#CostControl